Companies · Other Health Care

AMEDICA Corp

SALT LAKE CITY · Other Health Care

Diligence memoA one-page analyst read on AMEDICA Corp — recommendation, valuation, rhythm, risks.
$73.3M
Total raised · real
8
Rounds
0.6×
Latest step-up
Top 7%
Sector rank · raised
Series B
Latest stage · inferred · Mon Jun 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

AMEDICA Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.28× the median modeled value of Series B Other Health Care companies in 2013–2015 (85 peers) — value vs value, same stage and era.
Dormant
  • Last raise 12.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

AMEDICA Corp is one of 5376 Other Health Care companies tracked from SALT LAKE CITY. By capital raised it ranks among the largest (ahead of 94% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2010-02-26 Raised $11M (real) Modeled valuation $229M (est)Series A2010Series A · 2010-09-20 Raised $14M (real) Modeled valuation $275M (est)Series A2010Series B · 2011-03-04 Raised $22M (real) Modeled valuation $490M (est)Series B2011Series B · 2011-03-04 Raised $22M (real) Modeled valuation $490M (est)Series B2011Series B · 2012-12-17 Raised $540K (real) Modeled valuation $12M (est)Series B2012Series B · 2013-02-25 Raised $3.1M (real) Modeled valuation $69M (est)Series B2013Series B · 2013-02-25 Raised $3.1M (real) Modeled valuation $69M (est)Series B2013Series B · 2013-08-30 Raised $7.5M (real) Modeled valuation $166M (est)Series B2013Series B · 2013-08-30 Raised $9.5M (real) Modeled valuation $210M (est)Series B2013Series B · 2014-06-30 Raised $5.5M (real) Modeled valuation $123M (est)Series B2014+$14M+$22M+$22M+$540K+$3.1M+$3.1M+$7.5M+$9.5M+$5.5MCumulative $99M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$11.4M · 2010
Series A extension$13.6M · 2010
Series B$22.1M · 2011
Series B extension$22.1M · 2011
Series B extension$540K · 2012
Series B extension$3.1M · 2013
Series B extension$3.1M · 2013
Series B extension$7.5M · 2013
Series B extension$9.5M · 2013
Series B extension$5.5M · 2014

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$122.9M
Base estimate est.
$13.0M
Conservative case
$472.8M
Upside case
$30.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $229.1M · 2010-02-262010Series A · modeled $275.1M · 2010-09-20Series B · modeled $490.2M · 2011-03-04Series B · modeled $490.2M · 2011-03-04Series B · modeled $12.0M · 2012-12-17Series B · modeled $69.3M · 2013-02-25Series B · modeled $69.3M · 2013-02-25Series B · modeled $166.3M · 2013-08-30Series B · modeled $210.0M · 2013-08-30Series B · modeled $122.9M · 2014-06-302014
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
6.0 yr
Elapsed time used
12.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$16.9M/yr
Capital velocity
16.3 yr
On record since
2010
First round
10
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 30× above median
This company$73.3M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.3× of median
This company$5.5M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 5.6× above median
This company$122.9M
Sector median$22.1M

Raised more than 94% of sector peers (real $). Modeled value above 83% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #74 of 85.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Drynachan, Llc · Series B Raised $40.0M · modeled $886.2M (est)Vistria SHC Holdings, LLC · Series B Raised $39.7M · modeled $879.5M (est)Ebh Holding Company, Inc. · Series B Raised $70.9M · modeled $871.1M (est)Orthopediatrics Corp · Series B Raised $57.5M · modeled $864.0M (est)Assurerx Health, Inc · Series B Raised $51.5M · modeled $828.4M (est)IMRIS Inc. · Series B Raised $36.8M · modeled $816.0M (est)Remedy Partners, Inc. · Series B Raised $56.4M · modeled $795.3M (est)Hansen Medical Inc · Series B Raised $126.0M · modeled $775.4M (est)BCOM Investment Partners, LLC · Series B Raised $34.5M · modeled $764.3M (est)Michigan Critical Care Consultants, Inc. · Series B Raised $34.0M · modeled $753.2M (est)HY Holdings, Inc. · Series B Raised $33.0M · modeled $731.1M (est)Medical Solutions L.L.C. · Series B Raised $32.5M · modeled $720.0M (est)AMEDICA Corp (this company) Raised $73.3M · modeled $122.9M (est)AMEDICA Corp
CompanyStageRaised · realValue · estvs peer med.
Drynachan, LlcSeries B$40.0M$886.2M2.00×
Vistria SHC Holdings, LLCSeries B$39.7M$879.5M1.99×
Ebh Holding Company, Inc.Series B$70.9M$871.1M1.97×
Orthopediatrics CorpSeries B$57.5M$864.0M1.95×
Assurerx Health, IncSeries B$51.5M$828.4M1.87×
IMRIS Inc.Series B$36.8M$816.0M1.84×
Remedy Partners, Inc.Series B$56.4M$795.3M1.79×
Hansen Medical IncSeries B$126.0M$775.4M1.75×
BCOM Investment Partners, LLCSeries B$34.5M$764.3M1.72×
Michigan Critical Care Consultants, Inc.Series B$34.0M$753.2M1.70×
HY Holdings, Inc.Series B$33.0M$731.1M1.65×
Medical Solutions L.L.C.Series B$32.5M$720.0M1.62×
AMEDICA Corp this companySeries B$73.3M$122.9M0.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$11.4M2010-02-26$51.6M$229.1M90%
Series A$13.6M2010-09-20$62.0M$275.1M90%
Series B$22.1M2011-03-04$122.9M$490.2M90%
Series B$22.1M2011-03-04$122.9M$490.2M90%
Series B$540K2012-12-17$3.0M$12.0M90%
Series B$3.1M2013-02-25$17.4M$69.3M90%
Series B$3.1M2013-02-25$17.4M$69.3M90%
Series B$7.5M2013-08-30$41.7M$166.3M90%
Series B$9.5M2013-08-30$52.7M$210.0M90%
Series B$5.5M2014-06-30$30.8M$122.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$11.4M2010-02-26
    • First recorded raise — entered as Series A.
  2. Series A$13.6M2010-09-20
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  3. Series B$22.1M2011-03-04
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
  4. Series B$22.1M2011-03-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  5. Series B$540K2012-12-17
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 41.0× smaller than the prior — bridge or down round.
  6. Series B$3.1M2013-02-25
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 5.8× larger than the prior — scaling up.
  7. Series B$3.1M2013-02-25
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  8. Series B$7.5M2013-08-30
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
  9. Series B$9.5M2013-08-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  10. Series B$5.5M2014-06-30
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
Intelligence
2014 ~Q4
Modeled next raise · ~6mo cadence
$5.5M
Modeled next size est.range $5.5M$8.9M
0.6×
Last step-up
$16.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Eric K. Olson1 other2012-12
Jay M. Moyes1 other2012-12
Jeffrey S White1 other2014-06
Max E. Link1 other2014-06
Max E. Link, Ph.D.1 other2011-03
Ashok R. Khandkar2010-02
Ben E Shappley2011-03
Ben R. Shappley2010-02
Bryan J. McEntire2010-09
Bryan McEntire2010-02
B. Sonny M Bal2014-06
Christopher R. Whitfield2014-06
David E Truetzel2011-03
David M. Truetzel2012-12
David R. Truetzel2010-09
David W Treutzel2014-06
F. Karl J. Farnsworth2013-02
George M. Singer2012-12
Gregg Honigblum2010-02
Gregg J. Honigblum2010-09
Gregg R. Honigblum2011-03
James P Abraham2014-06
Jonathan J. Stupka2010-09
Jonathan Stupka2010-02
Registry & provenance

AMEDICA Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1269026
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
AristaMD, Inc.Other Health CareSeries B$71.2M$136.4Msame sector · same stage
Accumetrics IncOther Health CareSeries B$71.1M$132.9Msame sector · same stage
Tioga Cardiovascular, Inc.Other Health CareSeries B$69.8M$105.6Msame sector · same stage
PAVmed Inc.Other Health CareSeries B$69.1M$120.6Msame sector · same stage
Augmedix, Inc.Other Health CareSeries B$67.9M$113.2Msame sector · same stage
Omni Orthopaedics IncOther Health CareSeries B$65.6M$110.8Msame sector · same stage
Conceivable Life Sciences Inc.Other Health CareSeries B$63.5M$142.7Msame sector · same stage
Shoulder Innovations, Inc.Other Health CareSeries B$84.7M$106.8Msame sector · same stage
Frequently asked
How much funding has AMEDICA Corp raised?
AMEDICA Corp has raised approximately $73.3M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is AMEDICA Corp's estimated valuation?
Provath's modeled valuation for AMEDICA Corp is approximately $122.9M (modeled range $13.0M–$472.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AMEDICA Corp at?
AMEDICA Corp's latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Jun 30.
What does AMEDICA Corp do and where is it based?
AMEDICA Corp operates in the Other Health Care sector, based in SALT LAKE CITY.
Explore related

See where AMEDICA Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AMEDICA Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.